Opus Genetics (NASDAQ:IRD) Earns “Buy” Rating from HC Wainwright

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock.

Opus Genetics Stock Down 1.3 %

Shares of IRD stock opened at $1.11 on Wednesday. Opus Genetics has a 1 year low of $0.81 and a 1 year high of $2.65. The stock’s fifty day simple moving average is $1.15. The firm has a market cap of $34.88 million, a price-to-earnings ratio of -1.01 and a beta of 0.16.

Insider Transactions at Opus Genetics

In other news, CEO George Magrath acquired 100,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were bought at an average price of $0.98 per share, with a total value of $98,000.00. Following the purchase, the chief executive officer now owns 599,150 shares of the company’s stock, valued at approximately $587,167. This represents a 20.03 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.60% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.